Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus
Annals of the New York Academy of Sciences · 2023
DOI: 10.1111/nyas.15058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the New York Academy of Sciences, 2023. Verfasst von Yanan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing Municipal Key Laboratory for Oral Biomedical Engineering of Higher Educ…. Hauptthemen laut MEDLINE: Clostridium butyricum, Alveolar Bone Loss, Periodontitis, Diabetes Mellitus. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The gut microbiota is a bridge linking periodontitis and systemic diseases, such as diabetes mellitus (DM). The probiotic Clostridium butyricum MIYAIRI 588 (CBM588) is reportedly an effective therapeutic approach for gut dysbiosis. Here, in a mouse model, we explored the therapeutic effect of CBM588 on periodontal bone destruction in DM and DM‐associated periodontitis (DMP), as well as the underlying mechanism. Micro‐computed tomography revealed that DM and DMP both aggravated periodontal bone destruction, which was alleviated by intragastric supplementation with CBM588. Moreover, 16S rRNA sequencing and untargeted metabolite analysis indicated that CBM588 ameliorated DMP‐triggered dysbiosis and led to reduced oxidative stress associated with elevated 4‐hydroxybenzenemethanol (4‐HBA) in serum. Furthermore, in vitro and in vivo experiments found that the metabolite 4‐HBA promoted nuclear factor erythroid 2‐related factor 2 (Nrf2) signaling activation and modulated the polarization of macrophages, thus ameliorating inflammatory bone destruction in DMP. Our study demonstrates the protective effects of CBM588 in DM‐induced mice, with and without ligature‐induced periodontitis. The mechanism involves regulation of the gut microbiota and restoration of the integrity of the gut barrier to alleviate oxidative damage by elevating serum 4‐HBA. This study suggests the possibility of CBM588 as a therapeutic adjuvant for periodontal treatment in diabetes patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing Municipal Key Laboratory for Oral Biomedical Engineering of Higher Education, Stomatological Hospital of Chongqing Medical University, Chongq…
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Lu, M., Zhang, Y., Yuan, X., Zhou, M., Xu, X., Zhang, T., & Song, J. (2023). Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus. Annals of the New York Academy of Sciences. https://doi.org/10.1111/nyas.15058
Vancouver
Zhang Y, Lu M, Zhang Y, Yuan X, Zhou M, Xu X, et al. Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus. Annals of the New York Academy of Sciences. 2023. doi:10.1111/nyas.15058
BibTeX
@article{Zhang2023,
author = {Zhang, Yanan and Lu, Miao and Zhang, Yang and Yuan, Xulei and Zhou, Mengjiao and Xu, Xiaohui and Zhang, Tingwei and Song, Jinlin},
title = {Clostridium butyricum MIYAIRI 588 alleviates periodontal bone loss in mice with diabetes mellitus},
journal = {Annals of the New York Academy of Sciences},
year = {2023},
doi = {10.1111/nyas.15058}
}
EUVIMED